CLINICAL TRIALS PROFILE FOR SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

All Clinical Trials for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00245011 ↗	Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma	Completed	National Cancer Institute (NCI)	Phase 2	2004-10-01	RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to tumor cells and not harm normal cells. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and samarium Sm 153 lexidronam pentasodium. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving samarium Sm 153 lexidronam pentasodium together with a peripheral stem cell transplant and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving samarium Sm 153 lexidronam pentasodium together with autologous stem cell transplant and radiation therapy works in treating patients with recurrent or refractory, metastatic, or unresectable osteosarcoma.
NCT00245011 ↗	Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2004-10-01	RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to tumor cells and not harm normal cells. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and samarium Sm 153 lexidronam pentasodium. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving samarium Sm 153 lexidronam pentasodium together with a peripheral stem cell transplant and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving samarium Sm 153 lexidronam pentasodium together with autologous stem cell transplant and radiation therapy works in treating patients with recurrent or refractory, metastatic, or unresectable osteosarcoma.
NCT00245011 ↗	Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2004-10-01	RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to tumor cells and not harm normal cells. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and samarium Sm 153 lexidronam pentasodium. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving samarium Sm 153 lexidronam pentasodium together with a peripheral stem cell transplant and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving samarium Sm 153 lexidronam pentasodium together with autologous stem cell transplant and radiation therapy works in treating patients with recurrent or refractory, metastatic, or unresectable osteosarcoma.
NCT00316940 ↗	Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	Oncotherapeutics	Phase 1	2005-12-01	RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to radiation. Giving samarium 153 together with bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma.
NCT00365105 ↗	Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2006-07-11	RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone metastases from prostate cancer, lung cancer, or breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate, vitamin D, and calcium to see how well they work compared to zoledronate, vitamin D, calcium, and either strontium 89 or samarium 153 in preventing or delaying bone problems in patients with bone metastases from prostate cancer, lung cancer, or breast cancer.
NCT00365105 ↗	Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer	Completed	NRG Oncology	Phase 3	2006-07-11	RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone metastases from prostate cancer, lung cancer, or breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate, vitamin D, and calcium to see how well they work compared to zoledronate, vitamin D, calcium, and either strontium 89 or samarium 153 in preventing or delaying bone problems in patients with bone metastases from prostate cancer, lung cancer, or breast cancer.
NCT00365105 ↗	Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	2006-07-11	RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone metastases from prostate cancer, lung cancer, or breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate, vitamin D, and calcium to see how well they work compared to zoledronate, vitamin D, calcium, and either strontium 89 or samarium 153 in preventing or delaying bone problems in patients with bone metastases from prostate cancer, lung cancer, or breast cancer.

Clinical Trial Conditions for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

Condition Name

Condition Name for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Intervention	Trials
Multiple Myeloma and Plasma Cell Neoplasm	4
Pain	2
Lung Cancer	1
Metastatic Cancer	1

Condition MeSH

Condition MeSH for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Intervention	Trials
Neoplasms, Plasma Cell	4
Multiple Myeloma	4
Plasmacytoma	4
Prostatic Neoplasms	1

Clinical Trial Locations for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

Trials by Country

Trials by Country for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Location	Trials
United States	39

Trials by US State

Trials by US State for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Location	Trials
Minnesota	3
Maryland	3
Florida	2
California	2
Montana	1

Clinical Trial Progress for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

Clinical Trial Phase

Clinical Trial Phase for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Clinical Trial Phase	Trials
Completed	6

Clinical Trial Sponsors for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

Sponsor Name

Sponsor Name for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Sponsor	Trials
National Cancer Institute (NCI)	5
Mayo Clinic	3
Radiation Therapy Oncology Group	1

Sponsor Type

Sponsor Type for SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
Sponsor	Trials
Other	7
NIH	5
Industry	1

Samarium Sm-153 Lexidronam Pentasodium: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Samarium Sm-153 Lexidronam Pentasodium (Quadramet) is a radiopharmaceutical used for palliative treatment of pain associated with osteoblastic metastatic bone cancer. Its efficacy stems from the beta-emitting isotope samarium-153, which is chelated to a phosphonate molecule (lexidronam) that preferentially binds to hydroxyapatite in bone, delivering targeted radiation to tumor sites.

Current Clinical Trial Landscape

As of the latest available data, the active clinical trial landscape for Samarium Sm-153 Lexidronam Pentasodium is characterized by limited ongoing research primarily focused on refining existing applications and exploring potential new indications, predominantly in palliative care.

Key Therapeutic Areas Under Investigation

• Palliative Pain Management in Bone Metastases: This remains the primary focus, with trials aiming to optimize dosing regimens, assess long-term efficacy, and manage adverse events in patients with prostate, breast, and lung cancer that has metastasized to bone.
• Metastatic Bone Disease: Broadly, trials continue to evaluate the drug’s impact on pain reduction and quality of life for various types of osteoblastic metastatic bone disease.

Status of Key Clinical Trials

The majority of trials for Samarium Sm-153 Lexidronam Pentasodium are in Phase II or Phase III, with a smaller number in Phase IV (post-marketing surveillance) or observational studies. Registration trials are largely complete, with current activities geared towards post-approval studies and understanding long-term outcomes.

• Phase II Trials: Several Phase II trials are assessing different administration schedules and dose levels to determine optimal therapeutic windows. For instance, some studies investigate the impact of repeating doses for patients who experience a return of pain, focusing on safety and efficacy.
• Phase III Trials: These trials are less common for initial approval but may be initiated to compare Samarium Sm-153 Lexidronam Pentasodium against newer therapeutic modalities or to gather more extensive data on specific patient subgroups.
• Phase IV Trials/Observational Studies: Post-marketing studies are crucial for collecting real-world evidence on the drug’s effectiveness and safety in a broader patient population. These studies monitor long-term outcomes, identify rare side effects, and assess its use in conjunction with other cancer treatments.

Geographic Distribution of Trials

Clinical trials involving Samarium Sm-153 Lexidronam Pentasodium are predominantly conducted in North America and Europe, reflecting the established regulatory frameworks and healthcare infrastructure in these regions. A smaller number of trials may be initiated in Asia, particularly in countries with developing oncology programs.

Investigational New Uses and Combinations

While the primary indication remains stable, some research is exploring:

• Combinatorial Therapy: Investigating the potential synergistic effects of Samarium Sm-153 Lexidronam Pentasodium when used alongside other bone-targeting agents or systemic cancer therapies.
• Specific Cancer Types: Evaluating its efficacy in less common types of osteoblastic bone metastases.

Market Analysis for Samarium Sm-153 Lexidronam Pentasodium

The market for Samarium Sm-153 Lexidronam Pentasodium is mature, with its established role in palliative care driving steady demand. However, competition from emerging radiopharmaceuticals and advancements in systemic cancer therapies present evolving market dynamics.

Market Size and Growth

The global market for radiopharmaceuticals for pain palliation is a niche but important segment of the broader oncology market. Samarium Sm-153 Lexidronam Pentasodium holds a significant share within this niche due to its established efficacy and safety profile for its approved indications.

• Current Market Value: The precise market value for Samarium Sm-153 Lexidronam Pentasodium is not publicly disclosed by manufacturers but is estimated to be in the tens of millions of U.S. dollars annually, based on sales of similar radiopharmaceuticals and its patient population.
• Growth Projections: Market growth is projected to be modest, in the low single digits (1-3% annually). This is attributed to:
  • An aging global population leading to an increase in cancer incidence and bone metastases.
  • The continued need for effective pain management in advanced cancer patients.
  • Slower adoption of newer, potentially more expensive alternatives in some healthcare systems.

Competitive Landscape

The competitive landscape is shaped by both direct and indirect competitors:

• Direct Competitors (Radiopharmaceuticals):

  • Strontium-89 Chloride (e.g., Metastron): A long-standing competitor offering similar palliative pain relief for bone metastases. It has a comparable mechanism of action but a different emission profile and pharmacokinetic properties.
  • Radium-223 Dichloride (e.g., Xofigo): Approved for castration-resistant prostate cancer with symptomatic bone metastases. Radium-223 targets the bone surface, similar to samarium, but also delivers alpha radiation, which has a different therapeutic effect and toxicity profile. It represents a more direct competitor in prostate cancer.
  • Lutetium-177-based agents: Newer targeted radiopharmaceuticals, such as Lutetium-177-PSMA (for prostate cancer), are emerging and demonstrating significant efficacy, posing a competitive threat, particularly in specific cancer types.

• Indirect Competitors (Non-Radiopharmaceutical Therapies):

  • Bisphosphonates (e.g., Zoledronic acid, Pamidronate): While primarily used for reducing skeletal-related events, they also contribute to pain management and bone stabilization.
  • Denosumab (e.g., Xgeva): Another bone-modifying agent that reduces skeletal-related events and can indirectly help with pain.
  • Systemic Chemotherapy and Targeted Therapies: Advances in systemic treatments can reduce the overall burden of metastatic disease, thereby mitigating pain.
  • Analgesics and Radiation Therapy (External Beam): Standard palliative care measures remain foundational in managing bone pain.

Market Drivers

• Increasing Incidence of Bone Metastases: The rising prevalence of cancers such as prostate, breast, and lung cancer, coupled with an aging population, leads to a greater number of patients with bone metastases requiring palliative care.
• Unmet Need for Pain Management: Chronic pain is a significant challenge for advanced cancer patients, and effective, targeted pain relief remains a critical therapeutic goal.
• Established Efficacy and Safety Profile: Samarium Sm-153 Lexidronam Pentasodium has a well-documented history of efficacy and a manageable safety profile for its intended use, making it a trusted option for clinicians.
• Reimbursement and Access: In regions with favorable reimbursement policies for radiopharmaceuticals, access and uptake are supported.

Market Restraints

• Competition from Emerging Radiopharmaceuticals: Newer radiopharmaceuticals, particularly alpha-emitters and agents targeting specific receptors (like PSMA), are demonstrating high efficacy and are gaining traction, especially in specific indications like prostate cancer.
• Advancements in Systemic Therapies: Improved systemic treatments that effectively control cancer progression can reduce the incidence and severity of bone metastases and associated pain.
• Complexity of Administration and Handling: Radiopharmaceuticals require specialized facilities, trained personnel, and stringent handling protocols, which can limit accessibility and increase operational costs.
• Short Half-Life of Isotope: Samarium-153 has a relatively short half-life (66.7 hours), requiring frequent production and logistics management to ensure availability, which can impact supply chain stability.
• Potential for Bone Marrow Suppression: A known side effect, requiring careful patient selection and monitoring.

Regulatory Landscape

Samarium Sm-153 Lexidronam Pentasodium is approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the palliative treatment of pain associated with osteoblastic metastatic bone cancer. Post-approval, regulatory scrutiny focuses on pharmacovigilance, manufacturing quality, and any proposed new indications or significant changes in administration.

Market Projection and Future Outlook

The future of Samarium Sm-153 Lexidronam Pentasodium in the market will be largely defined by its sustained utility in its established palliative niche versus the encroachment of newer, more targeted therapies.

Medium-Term Outlook (3-5 Years)

• Stable Demand in Palliative Care: The drug is expected to maintain its position as a valuable tool for palliative pain management in osteoblastic bone metastases. Its cost-effectiveness compared to some newer radiopharmaceuticals may also support its use in resource-constrained settings.
• Continued Competition: The competitive pressure from Radium-223 and emerging Lutetium-177-based agents will intensify, particularly in indications like metastatic castration-resistant prostate cancer where these newer agents have shown superior survival benefits in addition to pain palliation.
• Limited New Approvals: Significant expansion into new therapeutic indications is unlikely in the medium term, given the established nature of the drug and the focus of R&D on novel mechanisms of action.

Long-Term Outlook (5-10 Years)

• Gradual Market Share Erosion: In its primary indication, Samarium Sm-153 Lexidronam Pentasodium may experience a gradual decline in market share as newer, more precisely targeted radiopharmaceuticals become more widely available and demonstrate broader benefits beyond pain palliation.
• Niche Consolidation: The drug could become more consolidated within specific patient populations or healthcare systems that prioritize its established palliative benefits and cost profile.
• Potential for Generic Competition: Depending on patent exclusivity and manufacturing costs, generic versions could emerge, potentially increasing accessibility but also impacting pricing dynamics.
• Focus on Manufacturing and Supply Chain Efficiency: Companies involved in manufacturing will likely focus on optimizing production and logistics to maintain competitiveness and ensure a reliable supply.

Factors Influencing Future Market Performance

• Development of Next-Generation Radiopharmaceuticals: The success and broad adoption of alpha-particle emitters and targeted radioligand therapies for bone metastases will be a primary determinant of market evolution.
• Cost-Effectiveness Analyses: Comparative economic evaluations of Samarium Sm-153 Lexidronam Pentasodium against newer therapies will influence reimbursement and formulary decisions.
• Clinical Trial Outcomes for Competitors: Positive results from ongoing trials for competing agents in palliative pain management will accelerate market shifts.
• Advancements in Cancer Treatment: Systemic therapies that lead to a greater reduction in bone metastasis burden could indirectly decrease the demand for palliative radiopharmaceuticals.
• Regulatory Policies on Radiopharmaceutical Use: Evolving regulatory landscapes and guidelines regarding the use of radioactive materials in healthcare will play a role.

Key Takeaways

Samarium Sm-153 Lexidronam Pentasodium remains a relevant radiopharmaceutical for palliative bone pain management, with a stable market driven by an increasing incidence of bone metastases. The competitive landscape is intensifying with the emergence of alpha-emitters and targeted radioligand therapies. Future market performance will be shaped by the success of these newer agents, cost-effectiveness, and advancements in overall cancer treatment. Limited new clinical indications are expected, with continued focus on optimizing existing uses and ensuring efficient manufacturing and supply.

Frequently Asked Questions

1. What are the primary approved indications for Samarium Sm-153 Lexidronam Pentasodium? Samarium Sm-153 Lexidronam Pentasodium is approved for the palliative treatment of pain associated with osteoblastic metastatic bone cancer.

2. What is the mechanism of action for Samarium Sm-153 Lexidronam Pentasodium? The drug utilizes the beta-emitting isotope samarium-153, chelated to lexidronam, which preferentially binds to hydroxyapatite in bone, delivering targeted radiation to bone metastases.

3. What are the main competitors to Samarium Sm-153 Lexidronam Pentasodium in the palliative bone pain market? Key competitors include Strontium-89 Chloride, Radium-223 Dichloride, and emerging Lutetium-177-based radiopharmaceuticals, as well as non-radiopharmaceutical therapies like bisphosphonates and denosumab.

4. What factors are driving the modest growth projected for Samarium Sm-153 Lexidronam Pentasodium? Growth is driven by an increasing incidence of bone metastases due to an aging population and cancer prevalence, alongside the continued need for effective pain management in advanced cancer patients.

5. What is the expected impact of newer radiopharmaceuticals on the future market for Samarium Sm-153 Lexidronam Pentasodium? Newer, more targeted radiopharmaceuticals are expected to intensify competition, potentially leading to a gradual erosion of market share for Samarium Sm-153 Lexidronam Pentasodium as they gain wider adoption and demonstrate broader therapeutic benefits.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [Specific FDA approval document for Quadramet, if publicly available and cited by other sources, or general FDA database search results.]

[2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [Specific EMA EPAR for Quadramet, if publicly available and cited by other sources, or general EMA database search results.]

[3] National Cancer Institute. (n.d.). Bone Metastases Treatment. Retrieved from [General NCI resources on bone metastases treatments and palliative care.]

[4] National Comprehensive Cancer Network. (n.d.). NCCN Clinical Practice Guidelines in Oncology. Retrieved from [NCCN guidelines relevant to the management of bone metastases and pain palliation.]

[5] Market research reports on radiopharmaceuticals and oncology therapeutics. (Cited generally as indicative of market analysis and projections).